David Buck
Stock Analyst at B. Riley Securities
(0.24)
# 4,253
Out of 4,944 analysts
14
Total ratings
21.43%
Success rate
-27.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Buck
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNOV MediciNova | Assumes: Buy | $22 | $1.27 | +1,632.28% | 2 | Mar 25, 2019 | |
| SUPN Supernus Pharmaceuticals | Maintains: Buy | $68 → $65 | $42.64 | +52.44% | 3 | Nov 12, 2018 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $219 → $190 | $117.12 | +62.23% | 4 | Nov 8, 2018 | |
| AMRX Amneal Pharmaceuticals | Maintains: Buy | $26 → $28 | $9.40 | +197.87% | 2 | Aug 22, 2018 | |
| ALKS Alkermes | Initiates: Buy | $60 | $28.63 | +109.57% | 1 | Jun 6, 2018 | |
| EVOK Evoke Pharma | Reinstates: Buy | $1,440 | $4.93 | +29,108.92% | 2 | Oct 19, 2017 |
MediciNova
Mar 25, 2019
Assumes: Buy
Price Target: $22
Current: $1.27
Upside: +1,632.28%
Supernus Pharmaceuticals
Nov 12, 2018
Maintains: Buy
Price Target: $68 → $65
Current: $42.64
Upside: +52.44%
Jazz Pharmaceuticals
Nov 8, 2018
Maintains: Buy
Price Target: $219 → $190
Current: $117.12
Upside: +62.23%
Amneal Pharmaceuticals
Aug 22, 2018
Maintains: Buy
Price Target: $26 → $28
Current: $9.40
Upside: +197.87%
Alkermes
Jun 6, 2018
Initiates: Buy
Price Target: $60
Current: $28.63
Upside: +109.57%
Evoke Pharma
Oct 19, 2017
Reinstates: Buy
Price Target: $1,440
Current: $4.93
Upside: +29,108.92%